Advertisement
Research Article| Volume 191, ISSUE 1, P90-97, March 2007

Homocysteine and coronary heart disease risk in the PRIME study

  • J.A. Troughton
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • J.V. Woodside
    Correspondence
    Corresponding author at: Department of Medicine, Mulhouse Building, Grosvenor Road, Belfast BT12 6BJ, UK. Tel.: +44 28 90632585; fax: +44 28 90235900.
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • I.S. Young
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • D. Arveiler
    Affiliations
    Strasbourg MONICA Project, Department of Epidemiology and Public Health, Faculty of Medicine, Strasbourg, France
    Search for articles by this author
  • P. Amouyel
    Affiliations
    Lille Monica Project, INSERM U508, Pasteur Institute of Lille, Lille, France
    Search for articles by this author
  • J. Ferrières
    Affiliations
    Toulouse MONICA Project, INSERM U588, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, Toulouse, France
    Search for articles by this author
  • P. Ducimetière
    Affiliations
    Coordinating Center, INSERM U258, Hôpital Paul Brousse, Villejuif, France
    Search for articles by this author
  • C.C. Patterson
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • F. Kee
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • J.W.G. Yarnell
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • A. Evans
    Affiliations
    Faculty of Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
    Search for articles by this author
  • on behalf of the PRIME Study Group
    Author Footnotes
    1 The PRIME Study is organized under an agreement between INSERM and the Merck, Sharpe and Dohme-Chibret Laboratory, with the following participating laboratories: The Strasbourg MONICA Project, Department of Epidemiology and Public Health, Faculty of Medicine, Strasbourg, France (D. Arveiler, B. Haas). The Toulouse MONICA Project, INSERM U558, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, Toulouse, France (J. Ferrières, J.B. Ruidavets). The Lille MONICA Project, INSERM U508, Pasteur Institute, Lille, France (P. Amouyel, M. Montaye). The Department of Epidemiology and Public Health, Queen's University, Belfast, Northern Ireland (A. Evans, J. Yarnell, F. Kee). The Department of Atherosclerosis, INSERM UR545, Lille, France (G. Luc, J.M. Bard). The Laboratory of Haematology, La Timone Hospital, Marseilles, France (I. Juhan-Vague). The Laboratory of Endocrinology, INSERM U326, Toulouse, France (B. Perret). The Vitamin Research Unit, The University of Bern, Bern, Switzerland (F. Gey). The Trace Element Laboratory, Department of Medicine, Queen's University Belfast, Northern Ireland (Jayne Woodside, Ian Young). The DNA Bank, INSERM U525, Paris, France (F. Cambien). The Coordinating Center, INSERM U258, Paris-Villejuif, France (P. Ducimetière, A. Bingham).
  • Author Footnotes
    1 The PRIME Study is organized under an agreement between INSERM and the Merck, Sharpe and Dohme-Chibret Laboratory, with the following participating laboratories: The Strasbourg MONICA Project, Department of Epidemiology and Public Health, Faculty of Medicine, Strasbourg, France (D. Arveiler, B. Haas). The Toulouse MONICA Project, INSERM U558, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, Toulouse, France (J. Ferrières, J.B. Ruidavets). The Lille MONICA Project, INSERM U508, Pasteur Institute, Lille, France (P. Amouyel, M. Montaye). The Department of Epidemiology and Public Health, Queen's University, Belfast, Northern Ireland (A. Evans, J. Yarnell, F. Kee). The Department of Atherosclerosis, INSERM UR545, Lille, France (G. Luc, J.M. Bard). The Laboratory of Haematology, La Timone Hospital, Marseilles, France (I. Juhan-Vague). The Laboratory of Endocrinology, INSERM U326, Toulouse, France (B. Perret). The Vitamin Research Unit, The University of Bern, Bern, Switzerland (F. Gey). The Trace Element Laboratory, Department of Medicine, Queen's University Belfast, Northern Ireland (Jayne Woodside, Ian Young). The DNA Bank, INSERM U525, Paris, France (F. Cambien). The Coordinating Center, INSERM U258, Paris-Villejuif, France (P. Ducimetière, A. Bingham).

      Abstract

      Introduction

      Despite recent meta-analyses suggesting that homocysteine is an independent predictor of coronary heart disease (CHD), there is debate regarding whether elevated homocysteine may be deleterious only in the presence of other risk factors, with which it acts synergistically to exert a multiplicative effect on CHD risk, emerging only as a CHD predictor in patients with pre-existing risk factors.
      The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study is a multicentre prospective study of 10 593 men from France and Northern Ireland, investigating cardiovascular risk factors. We investigated: (1) whether higher homocysteine is associated with increased CHD risk in the PRIME case-control cohort; (2) whether homocysteine interacts synergistically with pre-existing CHD risk factors.

      Methods

      Homocysteine was measured in 323 participants who had developed CHD at 5-year follow-up and in 638 matched controls.

      Results

      There was no significant difference in homocysteine between cases and controls (p = 0.18). Homocysteine was significantly higher in current smokers (geometric mean μmol/l (interquartile range μmol/l) 9.45 (7.43, 11.75)) compared with non-smokers (8.90 (7.32, 10.70); p = 0.007). There was a significant interaction between homocysteine, smoking and CHD risk (χ2 = 10.29, d.f. = 2, p = 0.006).

      Conclusions

      These findings suggest that elevated homocysteine is significantly associated with CHD risk in current smokers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ross R.
        The pathogenesis of atherosclerosis: a perspective for the 1990s.
        Nature. 1993; 362: 801-809
        • Heller R.F.
        • Chinn S.
        • Pedoe H.D.
        • Rose G.
        How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project.
        Br Med J (Clin Res Ed). 1984; 288: 1409-1411
        • Yarnell J.W.
        The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction.
        QJM. 1998; 91: 667-676
        • Scarabin P.Y.
        • Arveiler D.
        • Amouyel P.
        • et al.
        Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study.
        Atherosclerosis. 2003; 166: 103-109
        • Finkelstein J.D.
        Methionine metabolism in mammals.
        J Nutr Biochem. 1990; 1: 228-237
        • Refsum H.
        • Fiskerstrand T.
        • Guttormsen A.B.
        • Ueland P.M.
        Assessment of homocysteine status.
        J Inherit Metab Dis. 1997; 20: 286-294
        • Ueland P.M.
        • Refsum H.
        • Beresford S.A.A.
        • Vollset S.E.
        The controversy over homocysteine and cardiovascular risk.
        Am J Clin Nutr. 2000; 72: 324-332
      1. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.
        JAMA. 2002; 288: 2015-2022
        • Ford E.S.
        • Smith S.J.
        • Stroup D.F.
        • et al.
        Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies.
        Int J Epidemiol. 2002; 31: 59-70
      2. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised, trials. Homocysteine Lowering Trialists’ Collaboration.
        BMJ. 1998; 316: 894-898
        • Wald D.S.
        • Law M.
        • Morris J.K.
        Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.
        Br Med J. 2002; 325: 1202K-1206K
        • Rose G.A.
        • Blackburn H.
        • Gillum R.R.
        • Prineas R.J.
        Cardiovascular survey methods.
        2nd ed. World Health Organisation, Geneva1982 (Ref Type: Pamphlet)
        • Ducimetiere P.
        • Ruidavets J.B.
        • Montaye M.
        • Haas B.
        • Yarnell J.
        Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50–59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study.
        Int J Epidemiol. 2001; 30: 1057-1062
        • Ubbink J.B.
        • Hayward Vermaak W.J.
        • Bissbort S.
        Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum.
        J Chromatogr. 1991; 565: 441-446
        • Ubbink J.B.
        • Delport R.
        Homocysteine as atherothrombotic agent: is the bark worse than the bite?.
        Nutrition. 2000; 16: 672-674
        • Chasan-Taber L.
        • Selhub J.
        • Rosenberg I.H.
        • et al.
        A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians.
        J Am Coll Nutr. 1996; 15: 136-143
        • Verhoef P.
        • Hennekens C.H.
        • Allen R.H.
        • et al.
        Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery.
        Am J Cardiol. 1997; 79: 799-801
        • Folsom A.R.
        • Nieto F.J.
        • McGovern P.G.
        • et al.
        Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.
        Circulation. 1998; 98: 204-210
        • Fallon U.B.
        • Ben Shlomo Y.
        • Elwood P.
        • Ubbink J.B.
        • Smith G.D.
        Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up.
        Heart. 2001; 85: 153-158
        • Graham I.M.
        • Daly L.E.
        • Refsum H.M.
        • et al.
        Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.
        JAMA. 1997; 277: 1775-1781
        • O’Callaghan P.
        • Meleady R.
        • Fitzgerald T.
        • Graham I.
        Smoking and plasma homocysteine.
        Eur Heart J. 2002; 23: 1580-1586
        • Piyathilake C.J.
        • Hine R.J.
        • Dasanayake A.P.
        • et al.
        Effect of smoking on folate levels in buccal mucosal cells.
        Int J Cancer. 1992; 52: 566-569
        • Ortega R.M.
        • Lopez-Sobaler A.M.
        • Gonzalez-Gross M.M.
        • et al.
        Influence of smoking on folate intake and blood folate concentrations in a group of elderly Spanish men.
        J Am Coll Nutr. 1994; 13: 68-72
        • Weggemans R.M.
        • de Groot L.C.
        • Haller J.
        Factors related to plasma folate and vitamin B12. The SENECA study.
        Int J Food Sci Nutr. 1997; 48: 141-150
        • Cafolla A.
        • Dragoni F.
        • Girelli G.
        • et al.
        Folate status in Italian blood donors: relation to gender and smoking.
        Haematologica. 2000; 85: 694-698
        • Mansoor M.A.
        • Kristensen O.
        • Hervig T.
        • et al.
        Low concentrations of folate in serum and erythrocytes of smokers: methionine loading decreases folate concentrations in serum of smokers and nonsmokers.
        Clin Chem. 1997; 43: 2192-2194
        • Subar A.F.
        • Harlan L.C.
        • Mattson M.E.
        Food and nutrient intake differences between smokers and non-smokers in the US.
        Am J Public Health. 1990; 80: 1323-1329
        • Fehily A.M.
        • Phillips K.M.
        • Yarnell J.W.
        Diet, smoking, social class, and body mass index in the Caerphilly Heart Disease Study.
        Am J Clin Nutr. 1984; 40: 827-833
        • Piyathilake C.J.
        • Macaluso M.
        • Hine R.J.
        • Richards E.W.
        • Krumdieck C.L.
        Local and systemic effects of cigarette smoking on folate and vitamin B-12.
        Am J Clin Nutr. 1994; 60: 559-566
        • Dekou V.
        • Gudnason V.
        • Hawe E.
        • et al.
        Gene-environment and gene–gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men.
        Thromb Haemost. 2001; 85: 67-74
        • Nygard O.
        • Vollset S.E.
        • Refsum H.
        • et al.
        Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study.
        JAMA. 1995; 274: 1526-1533
        • Targher G.
        • Bertolini L.
        • Zenari L.
        • et al.
        Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes.
        Diabetes Care. 2000; 23: 524-528
        • Francis K.T.
        • Thompson R.W.
        • Krumdieck C.L.
        Reaction of tetrahydrofolic acid with cyanate from urea solutions: formation of an inactive folate derivative.
        Am J Clin Nutr. 1977; 30: 2028-2032
        • Abu K.M.
        • Watkins C.L.
        • Krumdieck C.L.
        Inactivation of B12 and folate coenzymes by butyl nitrite as observed by NMR: implications on one-carbon transfer mechanism.
        Biochem Biophys Res Commun. 1986; 135: 201-207
        • Frasca V.
        • Riazzi B.S.
        • Matthews R.G.
        In vitro inactivation of methionine synthase by nitrous oxide.
        J Biol Chem. 1986; 261: 15823-15826
        • Bergmark C.
        • Mansoor M.A.
        • Svardal A.
        • de Faire U.
        Redox status of plasma homocysteine and related aminothiols in smoking and nonsmoking young adults.
        Clin Chem. 1997; 43: 1997-1999
        • De Bree A.
        • Verschuren W.M.
        • Blom H.J.
        • Kromhout D.
        Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20–65 y.
        Am J Clin Nutr. 2001; 73: 1027-1033
        • Shimakawa T.
        • Nieto F.J.
        • Malinow M.R.
        • et al.
        Vitamin intake: a possible determinant of plasma homocyst(e)ine among middle-aged adults.
        Ann Epidemiol. 1997; 7: 285-293
        • Selhub J.
        • Jacques P.F.
        • Wilson P.W.
        • Rush D.
        • Rosenberg I.H.
        Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.
        JAMA. 1993; 270: 2693-2698
        • Bates C.J.
        • Mansoor M.A.
        • van der P.J.
        • et al.
        Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over.
        Eur J Clin Nutr. 1997; 51: 691-697
        • Kyhse-Andersen J.
        • Schmidt C.
        • Nordin G.
        • et al.
        Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate.
        Clin Chem. 1994; 40: 1921-1926